^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + bemcentinib (BGB324) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1440P - Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)
Published date:
10/16/2023
Excerpt:
BGBC008 is a ph2 open-label, single-arm study of bem+pembro in 2L NS NSCLC...Median OS and mPFS in KRAS mutated (KRASMT) (n=20) and KRAS wild-type (KRASWT)(n=36) were 14.1 vs 10.0 mths (p=0.49) and 9.8 vs 3.8 mths (p=0.009), respectively….The promising efficacy signal observed in KRASMT pts warrants further validation.
Trial ID:
